BioWorld

Oct. 12, 2009

View Archived Issues

Me-Too Drugs Not Dead Yet, but No Exceptions on Value

At last month's BioPharm America conference in San Francisco, biotech experts brushed aside the once-popular business model of using drug delivery or reformulation to provide incremental improvements to existing drugs. Read More

Money Raised Year to Date

Read More

When Biotechs Hit Hard Times, Leases Can Be the Last Straw

Read More

Money Raised By Biotech in 2009

Read More

Week in Review

Read More

Word on the Street

Read More

Week in Washington

Read More

FDA Approvals in September

Read More

Phase I Clinical Trials Update: September 2009

Read More

Phase II Clinical Trials Update: September 2009

Read More

Pivotal/Phase III Clinical Trials Update: September 2009

Read More

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Read More

Non-U.S. Clinical Trials And Regulatory Actions: September 2009

Read More

FDA Submissions, Approvals And Other Actions: September 2009

Read More

Stock Gainers and Losers For The Week

Read More

BioWorld Stock Report For Public Biotechnology Companies

Read More